EMA Management Board Reviewed Regulatory Progress
The board met in September 2026 to discuss operational updates and future leadership nominations.
Updated on Oct. 1, 2026 in Biotech
Live Poll
Do you trust that EU regulators will effectively manage the transition to modernized medical authorization systems?
During its September 2026 meeting, the European Medicines Agency Management Board evaluated progress on pharmaceutical applications and administrative developments. The board also established procedures for selecting its next Executive Director.
Why it matters
The agency is preparing for new pharmaceutical legislation and modernizing its data platforms to ensure the continued supply of critical medicines across the European Union. These updates aim to align internal systems with upcoming regulatory requirements.
The agency received 29 applications for human medicines and 7 for veterinary drugs in the first half of 2026. Currently, the Clinical Trials Information System manages over 14,000 trials, processing 200 new applications every month.
The players
European Medicines Agency
The agency is responsible for the scientific evaluation, supervision, and safety monitoring of medicines in the European Union.
European Commission
This executive arm of the European Union proposes legislation and implements decisions, including the Biotech Act.
The details
The board is focusing on adapting the Clinical Trials Information System to meet the standards of the proposed Biotech Act, which affects 70% of the platform's current functionality. Development of this modernized system is scheduled to commence in early 2027.
Timeline
The EMA Management Board met in September 2026.
Operations for the first half of 2026 were reviewed.
A detailed CTIS roadmap is scheduled for December 2026.
Modernization of the CTIS platform begins in early 2027.
Clinical trials regulation changes may take effect in early 2028.
The Tech Race
This modernization effort follows the European Commission's adoption of the Biotech Act proposal in December 2025. It positions the agency to transition from legacy clinical data management to a system capable of meeting stricter regulatory demands.
The modernization of the clinical trials platform aims to improve the availability and supply of critical medicines for patients. Users of the system, including researchers, will eventually navigate updated processes as the new regulations come into force.
The takeaway
The agency's proactive adjustment of its digital infrastructure ensures it remains prepared for shifting regulatory landscapes in international pharmaceutical markets. These administrative changes are essential for maintaining stable medical supply chains.
What happens next
The Board will convene an extraordinary meeting once the European Commission submits a shortlist of candidates for the Executive Director position.
Further reading
Learn more about advancements in the Biotech sector.
Source note: This article includes information reported by European Medicines Agency (EMA).
Live Poll
Do you trust that EU regulators will effectively manage the transition to modernized medical authorization systems?
